Dr. Cristiana Sieiro Santos delivers a vital expert analysis on the heterogeneous clinical manifestations and unpredictable disease course of Systemic Sclerosis, featured at the EULAR 2026 Congress. This brief highlights the crucial updates in early risk stratification, the progression of organ-specific complications like interstitial lung disease (ILD), and how deep clinical phenotyping is driving the shift toward precision medicine and targeted therapeutic intervention.

Video: https://medicaldigest.org/scientific-contents/interview:clinical-manifestations-and-disease-course-systemic-sclerosis

Dr. Victoria Werth provides an expert analysis of the EULAR 2026 session exploring the role of Toll-like receptor 7 and 8 (TLR7/8) inhibition in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). This recap looks beneath the surface at the underlying pathogenic mechanisms of the disease, highlighting the latest clinical data and new therapeutic perspectives on how targeting the TLR7/8 pathway could transform future treatment strategies and patient outcomes.

Video: https://medicaldigest.org/scientific-contents/interview:under-surface-new-perspectives-lupus-tlr78-inhibition

Dr. Marco Gattorno provides an essential overview of the EULAR 2026 session focused on the transition of young patients with autoinflammatory diseases from pediatric to adult rheumatology care. This recap highlights the practical and clinical implications for daily medical management, emphasizing the need for structured multidisciplinary protocols. The discussion explores how to maintain treatment continuity, empower young patients, and address the unique disease trajectories that cross the age divide.

Video: https://medicaldigest.org/scientific-contents/interview:transitioning-young-patients-autoinflammatory-diseases-adult-care-implications-daily-clinical-management

Professor Ruxandra Ionescu delivers an expert overview of the EULAR 2026 session dedicated to the advanced management of Rheumatoid Arthritis. This comprehensive recap explores the latest clinical evidence, emerging therapeutic pathways, and refined treat-to-target protocols designed to address complex, difficult-to-treat cases. The discussion highlights practical strategies for optimizing long-term outcomes, balancing drug safety, and improving overall quality of life for RA patients.

Video: https://medicaldigest.org/scientific-contents/interview:advanced-management-rheumatoid-arthritis-critical-updates-eular-2026

Dr. Elena Elefante provides an expert look into the EULAR 2026 joint session "Tired is not just a state of mind," focusing on the clinical realities of pathological fatigue in patients with rheumatic and musculoskeletal diseases (RMDs). This overview dives into how chronic fatigue is increasingly recognized as a complex biological symptom rather than a purely psychological state. The recap explores current challenges and advancements in defining, objectively measuring, and managing this debilitating condition to improve patient quality of life.

Video: https://medicaldigest.org/scientific-contents/interview:tired-not-just-state-mind-addressing-pathological-fatigue-eular-2026

Dr. Michael Zauner provides a comprehensive expert overview of the latest advancements in assessing disease activity in Psoriatic Arthritis, presented at the EULAR 2026 Congress. This recap explores the evolving role of multi-domain assessment tools, the integration of patient-reported outcomes, and how more precise tracking measures are shaping modern treat-to-target strategies to improve long-term joint and skin outcomes.

Video: https://medicaldigest.org/scientific-contents/interview:assessment-disease-activity-psoriatic-arthritis

Dr. Carel le Roux delivers an expert overview of the highly anticipated findings from the SYNCHRONIZE™ Phase 3 clinical studies, presented at the ADA Scientific Sessions. The discussion focuses on the clinical benefits of glucagon/GLP-1 receptor dual agonism, showcasing new data on survodutide. This recap highlights how targeting both pathways offers a powerful approach to weight management and metabolic health, marking a significant step forward in obesity care.

Video: https://medicaldigest.org/scientific-contents/interview:benefits-glucagonglp-1-receptor-dual-agonism-insights-synchronize-phase-3-studies-survodutide

Dr. Joshua Brody provides an expert overview of the most impactful clinical updates and essential takeaways from the 2026 ASCO Annual Meeting, focusing on groundbreaking advancements in lymphoma care. The recap explores the latest data on bispecific antibodies, including remarkable complete remission rates in Mantle Cell Lymphoma, crucial safety updates for outpatient administration, and the rapidly evolving role of frontline combination therapies in DLBCL.

Video: https://medicaldigest.org/scientific-contents/interview:lymphoma-highlights-and-key-takeaways-2026-asco-annual-meeting

Professor Giampaolo Bianchini discusses the evolving landscape of immunotherapy in early-stage breast cancer, focusing on predictive biomarkers, patient selection, and the integration of checkpoint inhibitors into neoadjuvant and adjuvant treatment settings to improve long-term outcomes.

Video: https://medicaldigest.org/scientific-contents/interview:immunotherapy-early-stage-breast-cancer-report-esmo-bc-2026

Professor Hope S. Rugo discusses the final overall survival results from the Phase 3 CAPItello-291 trial, evaluating the efficacy, long-term disease control, and safety of combining the AKT inhibitor capivasertib with fulvestrant for patients with AI-resistant, HR+/HER2− advanced breast cancer.

Video: https://medicaldigest.org/scientific-contents/interview:capitello-291-trial-final-overall-survival-results-capivasertib-and-fulvestrant-hrher2-advanced-breast-cancer